Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $101.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target upped by The Goldman Sachs Group from $90.00 to $101.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts also recently issued reports on the stock. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Kiniksa Pharmaceuticals International Price Performance

KNSA opened at $92.24 on Wednesday. The company’s 50 day simple moving average is $79.15 and its 200-day simple moving average is $60.03. The stock has a market capitalization of $7.20 billion, a P/E ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International has a one year low of $36.56 and a one year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. The firm had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. As a group, analysts anticipate that Kiniksa Pharmaceuticals International will post 1.26 EPS for the current year.

Insider Buying and Selling

In other news, CAO Michael Megna sold 4,600 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 12.7% in the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after acquiring an additional 421,347 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after purchasing an additional 128,417 shares in the last quarter. Spruce Street Capital LP increased its holdings in Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after purchasing an additional 326,081 shares in the last quarter. Bank of America Corp DE increased its holdings in Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after purchasing an additional 506,576 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in Kiniksa Pharmaceuticals International by 2.0% in the first quarter. Rice Hall James & Associates LLC now owns 608,416 shares of the company’s stock valued at $29,295,000 after purchasing an additional 11,985 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.